Compare Astena Holdings Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 19,891 Million (Small Cap)
8.00
NA
0.21%
0.49
8.80%
0.72
Revenue and Profits:
Net Sales:
16,557 Million
(Quarterly Results - Feb 2026)
Net Profit:
589 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
2.78%
0%
2.78%
1 Year
0.21%
0%
0.21%
2 Years
-2.43%
0%
-2.43%
3 Years
5.48%
0%
5.48%
4 Years
9.32%
0%
9.32%
5 Years
-37.12%
0%
-37.12%
Astena Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.81%
EBIT Growth (5y)
8.21%
EBIT to Interest (avg)
21.22
Debt to EBITDA (avg)
1.74
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
1.29
Tax Ratio
100.00%
Dividend Payout Ratio
33.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.25%
ROE (avg)
6.80%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
0.73
EV to EBIT
10.66
EV to EBITDA
6.55
EV to Capital Employed
0.82
EV to Sales
0.51
PEG Ratio
0.37
Dividend Yield
0.21%
ROCE (Latest)
7.66%
ROE (Latest)
8.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Feb'26 - QoQ
Feb'26
Nov'25
Change(%)
Net Sales
16,557.00
17,267.00
-4.11%
Operating Profit (PBDIT) excl Other Income
1,805.00
880.00
105.11%
Interest
119.00
56.00
112.50%
Exceptional Items
0.00
-13.00
100.00%
Consolidate Net Profit
589.00
551.00
6.90%
Operating Profit Margin (Excl OI)
69.60%
12.50%
5.71%
USD in Million.
Net Sales
QoQ Growth in quarter ended Feb 2026 is -4.11% vs 12.31% in Nov 2025
Consolidated Net Profit
QoQ Growth in quarter ended Feb 2026 is 6.90% vs 58.79% in Nov 2025
Annual Results Snapshot (Consolidated) - Nov'25
Nov'25
Nov'24
Change(%)
Net Sales
62,744.00
57,993.40
8.19%
Operating Profit (PBDIT) excl Other Income
5,446.00
5,402.90
0.80%
Interest
220.00
88.60
148.31%
Exceptional Items
-279.00
-4,525.70
93.84%
Consolidate Net Profit
2,179.00
-2,538.00
185.86%
Operating Profit Margin (Excl OI)
48.10%
48.60%
-0.05%
USD in Million.
Net Sales
YoY Growth in year ended Nov 2025 is 8.19% vs 11.56% in Nov 2024
Consolidated Net Profit
YoY Growth in year ended Nov 2025 is 185.86% vs -320.06% in Nov 2024
About Astena Holdings Co., Ltd. 
Astena Holdings Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






